arrow
R

Robert Zeiser

medical center university of freiburg albert ludwigs university
H指数:78
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infusion timing and outcomes after allogeneic hematopoietic cell transplantation across graft sources

异基因造血细胞移植后不同输注时机与移植物来源的结局

2026-11-060
PRE
Lung transplantation after allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

同种异基因造血干细胞移植后的肺移植:EBMT移植并发症工作组的研究

2026-10-260
PRE
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial

体外光opheresis治疗免疫检查点抑制剂疗法所致的类固醇难治性免疫相关不良反应:一项多中心Ib/II期临床试验

2026-10-230
OAAI
Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

纠正:基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较,用于接受异基因造血干细胞移植的AML患者,移植预处理强度为中等强度方案:代表EBMT急性白血病工作组进行的登记研究

2026-10-230
OAAI
Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg

高级黑色素瘤中的精准肿瘤学:来自弗赖堡分子肿瘤委员会的分子景观与个性化治疗建议

2026-10-210
OAAI
Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP

ROCK2抑制剤belumosudil对慢性GVHD的疗效与安全性:来自belumosudil MAP大型德奥人群多中心回顾性分析的结果

2026-10-050
PRE
Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较:在异基因无关供者移植且采用中间强度预处理方案的患者中治疗AML的登记研究——代表EBMT急性白血病工作组

2026-09-100
OAAI
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

2016年至2022年间EBMT中心中,17p缺失的骨髓瘤患者在接受AHSCT时,细胞遗传学异常的累积效应对其预后的影响

2026-09-050
OAAI
Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation

TP53突变特征及异基因造血细胞移植后急性髓系白血病的结局分析

2026-09-040
OA
Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease – a First-in-Human Trial

Gp120激活的同种异基因调节性T细胞预防移植物抗宿主病——一项首次人体试验

2026-08-310
OAAI
Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

移植前后鲁索利替尼预防可改善接受骨髓纤维化异基因造血细胞移植患者的预后

2026-07-220
OAAI
Minute-Scale Repeated Metabolic Probing of Living Cells Enabled by Rapid Parahydrogen-Based Hyperpolarization

通过快速顺磁性氢基超极化技术实现的分钟级活细胞重复代谢探针

2026-07-100
OAAI
A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia

异基因移植后急性白血病患者无白血病生存的综合性预后模型

2026-07-020
OA
Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies

单倍型相合移植联合移植后环磷酰胺不劣于9/10相合无关供者移植联合抗胸腺细胞球蛋白在髓系恶性肿瘤患者中的应用

2026-04-080
OAAI
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

异基因造血干细胞移植后复发的AML患者的突变谱变化

2026-04-030
OAAI